Previous Close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 5.00 |
Expire Date | 2024-11-15 |
Day's Range | 0.1000 - 0.1000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
HOLLISTON, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City on June 5, 2024. The Company’s presentation will be 2:00-2:25 PM ET on June 5th. The presentation will be webcast live and can be accessed through the investor relations sectio
HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference. To register for the presentation, o
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2024 Earnings Call Transcript May 7, 2024 Harvard Bioscience, Inc. misses on earnings expectations. Reported EPS is $-0.10815 EPS, expectations were $0.02. Harvard Bioscience, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]